Back to Search
Start Over
Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness
- Source :
- Experimental and Molecular Medicine, Vol 50, Iss 10, Pp 1-12 (2018)
- Publication Year :
- 2018
- Publisher :
- Nature Publishing Group, 2018.
-
Abstract
- Brain cancer: Enzyme target for potential therapy A drug that targets a key enzyme in aggressive brain cancer tumors could help tackle resistance to existing treatments. Glioblastoma is the most aggressive form of brain cancer and remains difficult to treat because the cancer cells can survive chemotherapy and radiotherapy. Certain cells within glioblastoma tumors have ‘stemness’ – unique stem cell-like metabolic characteristics that allow them to rapidly repair DNA damage and trigger relapse. Hyonchol Jang at the National Cancer Center in Goyang, South Korea and co-workers discovered that an enzyme called farnesyl diphosphate synthase (FDPS) helps maintain stemness in glioblastoma. The team then treated patient-derived glioblastoma cells with existing drugs known to inhibit FDPS. One such drug, which is already used to treat osteoporosis, inhibited the formation of secondary glioblastoma and may prove valuble in the treatment of brain cancer.
- Subjects :
- Medicine
Biochemistry
QD415-436
Subjects
Details
- Language :
- English
- ISSN :
- 12263613 and 20926413
- Volume :
- 50
- Issue :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- Experimental and Molecular Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f5bde652b6794bac89129022c500c7fa
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s12276-018-0166-2